As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
16 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast:
16 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast:
| Jul '25 |
+/-
%
|
||
| Revenue | 1.43 1.43 |
-
|
|
| Gross Profit | 0.84 0.84 |
-
|
|
| EBITDA | -104 -104 |
33%
33%
|
|
| EBIT (Operating Income) EBIT | -105 -105 |
33%
33%
|
|
| Net Profit | -102 -102 |
28%
28%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Ben Palleiko |
| Employees | 150 |
| Founded | 2004 |
| Website | www.kalvista.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


